Latest Clinuvel Pharmaceuticals (Asx:Cuv) News

Page 1 of 1
CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.
Victor Sage
Victor Sage
8 Dec 2025
Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.
Ada Torres
Ada Torres
16 Oct 2025
The European Medicines Agency has approved continuous bi-monthly dosing of CLINUVEL’s SCENESSE® for adult erythropoietic protoporphyria patients, removing previous annual dose limits and aligning Europe with US treatment standards.
Victor Sage
Victor Sage
23 Sept 2025
CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.
Ada Torres
Ada Torres
19 Sept 2025
Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.
Ada Torres
Ada Torres
28 Aug 2025
Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.
Ada Torres
Ada Torres
28 Aug 2025
Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.
Ada Torres
Ada Torres
28 Aug 2025
CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.
Ada Torres
Ada Torres
22 Aug 2025
CLINUVEL’s Phase II pilot study reveals afamelanotide monotherapy does not trigger repigmentation in vitiligo patients, underscoring the necessity of adjunct NB-UVB phototherapy.
Victor Sage
Victor Sage
18 June 2025
CLINUVEL Pharmaceuticals announces the full-time return of Managing Director Dr Philippe Wolgen, focusing on advancing critical product development and corporate initiatives, while Acting CEO Lachlan Hay continues until September 2025.
Victor Sage
Victor Sage
13 June 2025
CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.
Ada Torres
Ada Torres
7 May 2025
CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.
Victor Sage
Victor Sage
10 Feb 2025